IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

This study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed chronic leukemia monocytic (CMML1-2).Primary endpoint are Complete remission rate and Overall survival.

Trial Details

NCT ID
NCT06647862
Phase
PHASE3
Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • IMM01
  • Azacitidine
  • Placebo
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Nanning, Gaungxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Age ≥ 18 years old, regardless of gender;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  • Life expectancy ≥ 12 weeks;
  • Patients with CMML diagnosed according to WHO 2016 criteria, including CMML-1 and CMML-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →